Prescription drug · ANDA
Colesevelam Hydrochloride NDC 51407-336
Colesevelam hydrochloride 625 mg/1 · Tablet · Oral · Golden State Medical Supply, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 51407-336-18 | 51407033618 | 180 TABLET in 1 BOTTLE (51407-336-18)Marketed from Apr 6, 2021 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Colesevelam Hydrochloride
- Generic name (nonproprietary)
- colesevelam hydrochloride
- Active ingredients
- Colesevelam hydrochloride — 625 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 209946
- Marketing start
- Listing expires
- Other FDA classes
- Bile-acid Binding Activity (Mechanism)
- Identifiers
- Product ID 51407-336_45a21a31-0682-d96b-e063-6394a90abde3SPL ID 45a21a31-0682-d96b-e063-6394a90abde3SPL set ID c7058806-ad4f-6d5f-e053-2a95a90a35e8RxCUI 866910UNII P4SG24WI5Q
- Pharmacologic class
- Bile Acid Sequestrant
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N451407033618followed by a unit qualifier and the quantityPackage 51407-0336-18. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Colesevelam hydrochloride is a bile acid sequestrant indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia ( 1.1 ). reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH), unable to reach LDL-C target levels despite an adequate trial of diet and lifestyle modification ( 1.1 ). improve glycemic control in adults with type 2 diabetes mellitus ( 1.2 ). Limitations of Use ( 1.3 ): Do not use for treatment of type 1 diabetes or for diabetic ketoacidosis. Not studied in Fredrickson Type I, III, IV, and V dyslipidemias 1.1 Primary H…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 209946
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Colesevelam hydrochloride | Colesevelam hydrochloride 625 mg/1 | TabletOral | A-S Medication Solutions | 50090-7604 |
| Colesevelam hydrochloride | Colesevelam hydrochloride 625 mg/1 | TabletOral | A-S Medication Solutions | 50090-7605 |
| Colesevelam hydrochloride | Colesevelam hydrochloride 625 mg/1 | TabletOral | Cranbury Pharmaceuticals, LLC | 27808-190 |